Cargando…

12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women

PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Meng, Zhou, Chuanli, Zhu, Kai, Zhang, Yiran, Song, Mengxiong, Zhang, Hao, Tu, Qihao, Ma, Xuexiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778479/
https://www.ncbi.nlm.nih.gov/pubmed/31631990
http://dx.doi.org/10.2147/CIA.S224663
_version_ 1783456772377280512
author Kong, Meng
Zhou, Chuanli
Zhu, Kai
Zhang, Yiran
Song, Mengxiong
Zhang, Hao
Tu, Qihao
Ma, Xuexiao
author_facet Kong, Meng
Zhou, Chuanli
Zhu, Kai
Zhang, Yiran
Song, Mengxiong
Zhang, Hao
Tu, Qihao
Ma, Xuexiao
author_sort Kong, Meng
collection PubMed
description PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women who had experienced initial osteoporotic vertebral compression fractures (OVCFs) and received PKP plus 12-month TPTD (n=113) or basic treatment (BT) of calcium and vitamin D supplements (n=208) were retrospectively collected. The risk of NVCFs over each 6-month period in the TPTD group was evaluated and compared with the BT group using a logistic regression. Health-related quality of life (HRQoL, EQ-5D questionnaire), back pain [100 mm visual analog scale (VAS)] and bone mineral density (BMD) of the spine were analyzed using linear mixed models for repeated measures (LMMRM). RESULTS: Logistic regression analysis adjusting for baseline characteristics showed that patients in the TPTD group had a lower risk of NVCFs compared with those receiving BT during the final three observation intervals (6–12 months, OR=0.189, 95% CI=0.030–0.681, p=0.046; 12–18 months, OR=0.009, 95% CI=0.0001–0.111, p=0.001; 18–24 months, OR=0.024, 95% CI=0.0009–0.264, p=0.009, respectively). Significant improvements in adjusted EQ-5D and back pain VAS scores were identified in the TPTD group compared with the BT group, and this improvement was sustained for at least 12 months after teriparatide treatment was discontinued (both p<0.001). The BMD of the spine also showed a higher T-value in the TPTD group compared with the BT group (p<0.001). CONCLUSION: In routine clinical practice, for patients with OVCFs who receive the PKP procedure, TPTD treatment may be a preferable subsequent therapy because of its ability to reduce the incidence of NVCFs and sustain a high quality of life and back pain alleviation.
format Online
Article
Text
id pubmed-6778479
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67784792019-10-18 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women Kong, Meng Zhou, Chuanli Zhu, Kai Zhang, Yiran Song, Mengxiong Zhang, Hao Tu, Qihao Ma, Xuexiao Clin Interv Aging Original Research PURPOSE: Define the effectiveness of teriparatide (TPTD) treatment on reducing the incidence of new vertebral compression fractures (NVCFs) and back pain and improving quality of life after percutaneous kyphoplasty (PKP). METHODS: Two years of clinical follow-up data from primary osteoporotic women who had experienced initial osteoporotic vertebral compression fractures (OVCFs) and received PKP plus 12-month TPTD (n=113) or basic treatment (BT) of calcium and vitamin D supplements (n=208) were retrospectively collected. The risk of NVCFs over each 6-month period in the TPTD group was evaluated and compared with the BT group using a logistic regression. Health-related quality of life (HRQoL, EQ-5D questionnaire), back pain [100 mm visual analog scale (VAS)] and bone mineral density (BMD) of the spine were analyzed using linear mixed models for repeated measures (LMMRM). RESULTS: Logistic regression analysis adjusting for baseline characteristics showed that patients in the TPTD group had a lower risk of NVCFs compared with those receiving BT during the final three observation intervals (6–12 months, OR=0.189, 95% CI=0.030–0.681, p=0.046; 12–18 months, OR=0.009, 95% CI=0.0001–0.111, p=0.001; 18–24 months, OR=0.024, 95% CI=0.0009–0.264, p=0.009, respectively). Significant improvements in adjusted EQ-5D and back pain VAS scores were identified in the TPTD group compared with the BT group, and this improvement was sustained for at least 12 months after teriparatide treatment was discontinued (both p<0.001). The BMD of the spine also showed a higher T-value in the TPTD group compared with the BT group (p<0.001). CONCLUSION: In routine clinical practice, for patients with OVCFs who receive the PKP procedure, TPTD treatment may be a preferable subsequent therapy because of its ability to reduce the incidence of NVCFs and sustain a high quality of life and back pain alleviation. Dove 2019-10-01 /pmc/articles/PMC6778479/ /pubmed/31631990 http://dx.doi.org/10.2147/CIA.S224663 Text en © 2019 Kong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kong, Meng
Zhou, Chuanli
Zhu, Kai
Zhang, Yiran
Song, Mengxiong
Zhang, Hao
Tu, Qihao
Ma, Xuexiao
12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title_full 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title_fullStr 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title_full_unstemmed 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title_short 12-Month Teriparatide Treatment Reduces New Vertebral Compression Fractures Incidence And Back Pain And Improves Quality Of Life After Percutaneous Kyphoplasty In Osteoporotic Women
title_sort 12-month teriparatide treatment reduces new vertebral compression fractures incidence and back pain and improves quality of life after percutaneous kyphoplasty in osteoporotic women
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778479/
https://www.ncbi.nlm.nih.gov/pubmed/31631990
http://dx.doi.org/10.2147/CIA.S224663
work_keys_str_mv AT kongmeng 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT zhouchuanli 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT zhukai 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT zhangyiran 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT songmengxiong 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT zhanghao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT tuqihao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen
AT maxuexiao 12monthteriparatidetreatmentreducesnewvertebralcompressionfracturesincidenceandbackpainandimprovesqualityoflifeafterpercutaneouskyphoplastyinosteoporoticwomen